The genetically engineered mouse model with Probasin-mediated deletion of Pten and Spry2 (namely PbCre Ptenfl/flSpry2fl/+, referred to as the SP model hereafter) models clinical invasive prostate cancer (12, 13). Here, SPRY2 is linked to prostate carcinoma.